Rectal indomethacin and somatostatin combination most effective for preventing post-ERCP pancreatitisNew data shows best way to prevent pancreatitis after ERCP

This network meta-analysis evaluated the efficacy of various prophylactic interventions for patients undergoing endoscopic retrograde cholangiopancreatography (ERCP) to prevent post-ERCP pancreatitis (PEP). The analysis included a large total sample size of 15627 patients. The primary objective was to compare rectal nonsteroidal anti-inflammatory drugs (NSAIDs), aggressive hydration with Lactated Ringer's solution (ALRS), somatostatin, and various combinations against placebo in the prevention of PEP.

The interventions evaluated included somatostatin monotherapy, rectal indomethacin monotherapy, and a combination of rectal indomethacin and somatostatin. These were compared against a placebo group to determine the most effective strategy for reducing the incidence of post-procedure complications.

Regarding the primary outcome of preventing PEP, all three active interventions demonstrated superior efficacy compared to placebo. Somatostatin showed an odds ratio (OR) of 0.49 (95% CI: 0.34-0.71). Rectal indomethacin alone showed an OR of 0.63 (95% CI: 0.44-0.9). The combination of rectal indomethacin and somatostatin demonstrated the greatest reduction in risk, with an OR of 0.31 (95% CI: 0.14-0.69). In terms of SUCRA ranking for PEP prevention, the combination therapy achieved a score of 80.9%, identifying it as the best preventive strategy among those studied.

For the secondary outcome of preventing post-ERCP hyperamylasemia (PEHA), all active interventions again outperformed placebo. Somatostatin showed an OR of 0.18 (95% CI: 0.1-0.33). Rectal indomethacin monotherapy showed an OR of 0.68 (95% CI: 0.55-0.84). The combination of rectal indomethacin and somatostatin showed an OR of 0.45 (95% CI: 0.28-0.73). Notably, the combination therapy received a SUCRA ranking of 100% for PEHA prevention, identifying it as the most efficacious modality for this specific outcome.

Safety and tolerability data were reported regarding complications such as bleeding and perforation. The study found that the combination of rectal indomethacin and somatostatin was associated with the lowest risk of bleeding (77.5%) and perforation (93.8%). These figures suggest a favorable safety profile for the combined regimen compared to other interventions.

These results provide a structured comparison of prophylactic agents in the management of acute pancreatitis risks following ERCP. While the study identifies the combination as highly effective, it is important to note that SUCRA rankings do not always translate directly into clinically meaningful superiority. The findings highlight the potential for combined pharmacological approaches to mitigate common post-procedure complications.

Several methodological limitations were identified. There was a limited number of studies specifically assessing the combination of rectal indomethacin and somatostatin, which may impact the certainty of certain rankings. Additionally, while SUCRA scores are useful for ranking, they do not always imply clinically significant differences between treatments. These factors should be considered when interpreting the magnitude of benefit over monotherapies.

Clinically, these results suggest that a combination of rectal indomethacin and somatostatin may be a highly effective strategy for preventing both PEP and PEHA in patients undergoing ERCP. This approach appears to offer superior efficacy compared to single-agent therapies while maintaining a favorable safety profile regarding bleeding and perforation. However, the clinical significance of the 100% SUCRA ranking for PEHA must be interpreted with caution due to the limited number of studies available for specific combinations. Questions remain regarding the long-term impact of these interventions on overall patient outcomes beyond immediate post-procedure complications. Furthermore, more large-scale trials are needed to confirm the clinical significance of the combination therapy over individual components in diverse patient populations.